WuXi Chemistry

We are proud to announce WuXi AppTec has been listed as one of TIME’s Best Companies in Sustainable Growth of 2025! This recognition underscores our continued dedication to embedding #ESG into every aspect of our operations – to better develop therapies for greater positive impact for patients and the healthcare industry. Read more: https://lnkd.in/eMVWghg8

As we step into 2025, we look forward to continuing our partnership and supporting your success in the year ahead. Happy New Year from all of us at WuXi STA and WuXi TIDES!

As we celebrate the holiday season, we are deeply grateful for our customers, partners, and colleagues around the globe. Your trust, collaboration, and unwavering support have been the foundation of everything we’ve achieved together in 2024.   This season reminds us of the values we cherish most—connection, innovation, and the shared commitment to transforming lives. Through our unique #CRDMO model and the passion of our global team, we’ve continued to enable our partners to bring hope to patients in need.   From all of us at WuXi AppTec, we wish you and your loved ones a joyful holiday season filled with warmth, peace, and togetherness. Here’s to another year of making a difference, together.

With over 200 β-amino acid products available for direct purchase on the WuXi TIDES Online Shop, discovering the right products to add structural diversity in your peptide therapeutic is straight-forward. Browse our portfolio of unnatural amino acids today and register online to shop now. https://lnkd.in/eHmtunSx

Radionuclide Drug Conjugates (RDCs) have shown great potential in early-stage tumor imaging and radiopharmaceutical therapy. In this WuXi TIDES case study, discovery how our integrated CMC services enabled a seamless transition from discovery to process development and manufacturing, across both small molecules and peptides. Our approach accelerated the development of a complex RDC candidate, achieving milligram-scale discovery synthesis in just 1 month and kilogram-scale manufacturing in only 3 months, paving the way for a successful #IND submission. Learn more: https://lnkd.in/g6AmChYd #Peptide #SmallMolecule #Radiopharmaceutical #DrugConjugates #DrugDevelopment #CRDMO

Our latest whitepaper explores advanced, data-driven approaches to benchmark and control critical impurities in nucleoside phosphoramidites—key building blocks in therapeutic oligonucleotides. By enhancing reproducibility, scalability, and regulatory compliance, WuXi TIDES produces high-quality amidites and provides comprehensive support throughout the oligonucleotide drug development process, from discovery through commercialization.   WuXi TIDES simplifies regulatory submissions for our customers by documenting select amidite products and PMO monomers in Drug Master Files (DMFs)—comprehensive FDA filings that provide detailed records of our manufacturing and quality control processes. Moreover, WuXi TIDES Catalog Products now offers over 600 amidite products, available for direct purchase online, with select amidites stocked globally in the US and Europe.   Download the whitepaper to learn more: https://lnkd.in/eyfeT4ca

WuXi TIDES Catalog Products has expanded its portfolio to now offer a nucleotide portfolio, featuring nucleoside triphosphates (NTPs) for mRNA synthesis, deoxynucleotides (dNTPs) and modified NTP products for innovative enzymatic synthesis solutions. Additionally, we offer cap precursor reagents to provide high-quality solutions for the synthesis of capping reagents.   To learn more and discover our new product offerings: https://lnkd.in/e4naERiv

This December marks WuXi AppTec’s 24th anniversary! For 24 years, our belief that “every drug can be made and every disease can be treated” has continued to inspire us as we look to the future with determination and optimism. Starting from a single laboratory, we have grown into a global enterprise with 32 R&D and manufacturing sites worldwide, dedicated to advancing breakthroughs in life-sciences. Thank you to our customers, partners, and global teams - your commitment to our mission of enabling transformative solutions has been the heartbeat of our success. Together, we’re not just imagining a healthier world - we are building it.

To meet the growing global demand for peptide therapeutics, WuXi TIDES is pleased to announce the expansion of our Solid Phase Peptide Synthesis (SPPS) capabilities with an additional 9,000 L of capacity at our Changzhou site, including reactors ranging from 500 L to 3,000 L. We now offer over 41,000 L of SPPS capacity! This expansion further enhances our integrated peptide CRDMO services, enabling us to accelerate the development of novel peptide therapeutics from discovery through clinical development and commercialization. By continuing to strengthen our platform capabilities, we aim to stay ahead of market needs and provide our partners with expertise, quality, and reliability. Stay tuned! We have more SPPS capacity expansions planned for 2025 … Learn more: https://lnkd.in/g6AmChYd

As we celebrate Thanksgiving, our global teams at WuXi STA and WuXi TIDES want to express heartfelt gratitude to our clients, partners, and colleagues who make our work possible. Thank you for your trust and support. Wishing you and your loved ones a joyful and peaceful Thanksgiving. #Thanksgiving #Gratitude #WuXiSTA #WuXiTIDES